Trump's pharmaceutical gambit exploits America's leverage as the world's largest drug market while threatening free-market solutions — import liberalization and patent reform — that Big Pharma has blocked through lobbying. By bypassing congressional gridlock and directly confronting an industry that's bilked consumers for decades, he's weaponizing executive power for the people.
Trump's voluntary price reduction gambit is economic theater masquerading as policy. Rather than confronting America's broken pharmaceutical pricing system, he's pursuing a dangerous zero-sum strategy that would force other nations to subsidize the U.S.' dysfunction while delivering negligible savings to Americans — a cynical deflection that perpetuates the very problems he claims to solve.